Jubilant Pharmova names Ashish Mukkirwar as CFO
Arun Kumar Sharma steps down into an advisory role as the company works through regulatory hurdles at its Montreal facility.
— 3 earlier stories on Jubilant Pharmova Ltd. →What's new with Jubilant Pharmova Ltd.
- Arun Kumar Sharma resigned as CFO effective May 22 and moved to an advisory role.
- Ashish Mukkirwar starts as CFO on May 23.
- Mukkirwar brings experience from Glenmark, Moelis, and UBS.
Why this matters for Jubilant Pharmova Ltd.
The board kept the outgoing CFO in an advisory role to manage the handover. Mukkirwar takes the reins while the Montreal plant remains under regulatory pressure. The next test is how he addresses those specific operational constraints.
What we're watching
- How Mukkirwar addresses the Montreal plant's regulatory status.
- Whether Sharma's advisory role leads to a full departure.
- The new CFO's approach to capital allocation.
The full read
Jubilant Pharmova is changing finance chiefs. Arun Kumar Sharma resigned as CFO on May 22 and moved into an advisory role. Ashish Mukkirwar takes his place on May 23. Mukkirwar brings two decades of experience, including senior finance roles at Glenmark and banking experience at Moelis and UBS. The transition is orderly, without the suddenness that often causes uncertainty. Mukkirwar starts with a full plate. Jubilant Pharmova is working through regulatory issues at its Montreal site, a problem that remains a primary drag on operations. Management keeping Sharma in an advisory role attempts to provide continuity during this exchange. The next test is whether the new CFO can fix the Montreal issues while keeping the company on its current path. No more is known about the shift until the new CFO takes control.